comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 22:22:33 - browse：28893

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

WSS

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Covid vaccine financial winners and losers, from Pfizer to Novavax

The FDA must approve intranasal treatments for anaphylaxis

Morgan Health, with ambitious aims, wants you to know it’s still here

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

The FDA must approve intranasal treatments for anaphylaxis

focus

comprehensive

hotspot

In age of alternative facts, a scholarly course on calling out crap

U.K. sequencing study surfaces new findings about tumor DNA

Wildfire smoke exposes gaps in outdoor worker protections

Eliminate the waiting period for sterilization covered by Medicaid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Feng Zhang, Grail founder join forces on new gene editing startup

Peter Hotez and the public health issue of online harassment

White House finalizes ITC's import ban of latest Apple Watches

How one medical school became remarkably diverse

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

focus

AdventHealth escalates lawsuit against insurance vendor Multiplan

U.K. sequencing study surfaces new findings about tumor DNA

White House finalizes ITC's import ban of latest Apple Watches

Why psychiatrists like me stop taking insurance

Why psychiatrists like me stop taking insurance

3 medical device trends to watch in 2024

focus

hotspot

hotspot

focus